CovidFranceV1, Main, Exploration, bibRecord, 001881

'All In': a pragmatic framework for COVID-19 testing and action on a global scale.

Identifieur interne : 001881 ( Main/Exploration ); précédent : 001880; suivant : 001882

'All In': a pragmatic framework for COVID-19 testing and action on a global scale.

Auteurs : Syril D. Pettit [États-Unis] ; Keith R. Jerome [États-Unis] ; David Rouquié [France] ; Bernard Mari [France] ; Pascal Barbry [France] ; Yasunari Kanda [Japon] ; Mineo Matsumoto [Japon] ; Susan Hester [États-Unis] ; Leah Wehmas [États-Unis] ; Jason W. Botten [États-Unis] ; Emily A. Bruce [États-Unis]

Source :

EMBO molecular medicine [ 1757-4684 ] ; 2020.

RBID : pubmed:32375201

Descripteurs français

KwdFr :
- ARN viral (analyse), Betacoronavirus (génétique), Betacoronavirus (isolement et purification), Humains (MeSH), Infections à coronavirus (diagnostic), Infections à coronavirus (virologie), Infections à coronavirus (épidémiologie), Pandémies (MeSH), Planification stratégique (MeSH), Pneumopathie virale (diagnostic), Pneumopathie virale (virologie), Pneumopathie virale (épidémiologie), RT-PCR (MeSH), Santé mondiale (MeSH), Techniques de laboratoire clinique (MeSH).
MESH :
- analyse : ARN viral.
- diagnostic : Infections à coronavirus, Pneumopathie virale.
- génétique : Betacoronavirus.
- isolement et purification : Betacoronavirus.
- virologie : Infections à coronavirus, Pneumopathie virale.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Humains, Pandémies, Planification stratégique, RT-PCR, Santé mondiale, Techniques de laboratoire clinique.

English descriptors

KwdEn :
- Betacoronavirus (genetics), Betacoronavirus (isolation & purification), Clinical Laboratory Techniques (MeSH), Coronavirus Infections (diagnosis), Coronavirus Infections (epidemiology), Coronavirus Infections (virology), Global Health (MeSH), Humans (MeSH), Pandemics (MeSH), Pneumonia, Viral (diagnosis), Pneumonia, Viral (epidemiology), Pneumonia, Viral (virology), RNA, Viral (analysis), Reverse Transcriptase Polymerase Chain Reaction (MeSH), Strategic Planning (MeSH).
MESH :
- chemical , analysis : RNA, Viral.
- diagnosis : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- genetics : Betacoronavirus.
- isolation & purification : Betacoronavirus.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Clinical Laboratory Techniques, Global Health, Humans, Pandemics, Reverse Transcriptase Polymerase Chain Reaction, Strategic Planning.

Abstract

Current demand for SARS-CoV-2 testing is straining material resource and labor capacity around the globe. As a result, the public health and clinical community are hindered in their ability to monitor and contain the spread of COVID-19. Despite broad consensus that more testing is needed, pragmatic guidance toward realizing this objective has been limited. This paper addresses this limitation by proposing a novel and geographically agnostic framework (the 4Ps framework) to guide multidisciplinary, scalable, resource-efficient, and achievable efforts toward enhanced testing capacity. The 4Ps (Prioritize, Propagate, Partition, and Provide) are described in terms of specific opportunities to enhance the volume, diversity, characterization, and implementation of SARS-CoV-2 testing to benefit public health. Coordinated deployment of the strategic and tactical recommendations described in this framework has the potential to rapidly expand available testing capacity, improve public health decision-making in response to the COVID-19 pandemic, and/or to be applied in future emergent disease outbreaks.

DOI: 10.15252/emmm.202012634
PubMed: 32375201
PubMed Central: PMC7267598

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001433
to stream Main, to step Curation: 001433

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">'All In': a pragmatic framework for COVID-19 testing and action on a global scale.</title>
<author><name sortKey="Pettit, Syril D" sort="Pettit, Syril D" uniqKey="Pettit S" first="Syril D" last="Pettit">Syril D. Pettit</name>
<affiliation wicri:level="2"><nlm:affiliation>Health and Environmental Sciences Institute, Washington, DC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Health and Environmental Sciences Institute, Washington, DC</wicri:regionArea>
<placeName><region type="state">District de Columbia</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jerome, Keith R" sort="Jerome, Keith R" uniqKey="Jerome K" first="Keith R" last="Jerome">Keith R. Jerome</name>
<affiliation wicri:level="4"><nlm:affiliation>Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
<settlement type="city">Seattle</settlement>
</placeName>
<orgName type="university">Université de Washington</orgName>
</affiliation>
</author>
<author><name sortKey="Rouquie, David" sort="Rouquie, David" uniqKey="Rouquie D" first="David" last="Rouquié">David Rouquié</name>
<affiliation wicri:level="1"><nlm:affiliation>SAS Bayer Crop Science, Sophia Antipolis, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>SAS Bayer Crop Science, Sophia Antipolis</wicri:regionArea>
<wicri:noRegion>Sophia Antipolis</wicri:noRegion>
<wicri:noRegion>Sophia Antipolis</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mari, Bernard" sort="Mari, Bernard" uniqKey="Mari B" first="Bernard" last="Mari">Bernard Mari</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), CNRS, Université Côte d'Azur, Valbonne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), CNRS, Université Côte d'Azur, Valbonne</wicri:regionArea>
<wicri:noRegion>Valbonne</wicri:noRegion>
<wicri:noRegion>Valbonne</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Barbry, Pascal" sort="Barbry, Pascal" uniqKey="Barbry P" first="Pascal" last="Barbry">Pascal Barbry</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), CNRS, Université Côte d'Azur, Valbonne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), CNRS, Université Côte d'Azur, Valbonne</wicri:regionArea>
<wicri:noRegion>Valbonne</wicri:noRegion>
<wicri:noRegion>Valbonne</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kanda, Yasunari" sort="Kanda, Yasunari" uniqKey="Kanda Y" first="Yasunari" last="Kanda">Yasunari Kanda</name>
<affiliation wicri:level="1"><nlm:affiliation>National Institute of Health Sciences, Kanagawa, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>National Institute of Health Sciences, Kanagawa</wicri:regionArea>
<wicri:noRegion>Kanagawa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Matsumoto, Mineo" sort="Matsumoto, Mineo" uniqKey="Matsumoto M" first="Mineo" last="Matsumoto">Mineo Matsumoto</name>
<affiliation wicri:level="3"><nlm:affiliation>Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Pharmaceuticals and Medical Devices Agency, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hester, Susan" sort="Hester, Susan" uniqKey="Hester S" first="Susan" last="Hester">Susan Hester</name>
<affiliation wicri:level="2"><nlm:affiliation>Office of Research and Development, Environmental Protection Agency, Research Triangle Park, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Office of Research and Development, Environmental Protection Agency, Research Triangle Park, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wehmas, Leah" sort="Wehmas, Leah" uniqKey="Wehmas L" first="Leah" last="Wehmas">Leah Wehmas</name>
<affiliation wicri:level="2"><nlm:affiliation>Office of Research and Development, Environmental Protection Agency, Research Triangle Park, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Office of Research and Development, Environmental Protection Agency, Research Triangle Park, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Botten, Jason W" sort="Botten, Jason W" uniqKey="Botten J" first="Jason W" last="Botten">Jason W. Botten</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT</wicri:regionArea>
<placeName><region type="state">Vermont</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bruce, Emily A" sort="Bruce, Emily A" uniqKey="Bruce E" first="Emily A" last="Bruce">Emily A. Bruce</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT</wicri:regionArea>
<placeName><region type="state">Vermont</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32375201</idno>
<idno type="pmid">32375201</idno>
<idno type="doi">10.15252/emmm.202012634</idno>
<idno type="pmc">PMC7267598</idno>
<idno type="wicri:Area/Main/Corpus">001433</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001433</idno>
<idno type="wicri:Area/Main/Curation">001433</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001433</idno>
<idno type="wicri:Area/Main/Exploration">001433</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">'All In': a pragmatic framework for COVID-19 testing and action on a global scale.</title>
<author><name sortKey="Pettit, Syril D" sort="Pettit, Syril D" uniqKey="Pettit S" first="Syril D" last="Pettit">Syril D. Pettit</name>
<affiliation wicri:level="2"><nlm:affiliation>Health and Environmental Sciences Institute, Washington, DC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Health and Environmental Sciences Institute, Washington, DC</wicri:regionArea>
<placeName><region type="state">District de Columbia</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jerome, Keith R" sort="Jerome, Keith R" uniqKey="Jerome K" first="Keith R" last="Jerome">Keith R. Jerome</name>
<affiliation wicri:level="4"><nlm:affiliation>Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
<settlement type="city">Seattle</settlement>
</placeName>
<orgName type="university">Université de Washington</orgName>
</affiliation>
</author>
<author><name sortKey="Rouquie, David" sort="Rouquie, David" uniqKey="Rouquie D" first="David" last="Rouquié">David Rouquié</name>
<affiliation wicri:level="1"><nlm:affiliation>SAS Bayer Crop Science, Sophia Antipolis, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>SAS Bayer Crop Science, Sophia Antipolis</wicri:regionArea>
<wicri:noRegion>Sophia Antipolis</wicri:noRegion>
<wicri:noRegion>Sophia Antipolis</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mari, Bernard" sort="Mari, Bernard" uniqKey="Mari B" first="Bernard" last="Mari">Bernard Mari</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), CNRS, Université Côte d'Azur, Valbonne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), CNRS, Université Côte d'Azur, Valbonne</wicri:regionArea>
<wicri:noRegion>Valbonne</wicri:noRegion>
<wicri:noRegion>Valbonne</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Barbry, Pascal" sort="Barbry, Pascal" uniqKey="Barbry P" first="Pascal" last="Barbry">Pascal Barbry</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), CNRS, Université Côte d'Azur, Valbonne, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), CNRS, Université Côte d'Azur, Valbonne</wicri:regionArea>
<wicri:noRegion>Valbonne</wicri:noRegion>
<wicri:noRegion>Valbonne</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kanda, Yasunari" sort="Kanda, Yasunari" uniqKey="Kanda Y" first="Yasunari" last="Kanda">Yasunari Kanda</name>
<affiliation wicri:level="1"><nlm:affiliation>National Institute of Health Sciences, Kanagawa, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>National Institute of Health Sciences, Kanagawa</wicri:regionArea>
<wicri:noRegion>Kanagawa</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Matsumoto, Mineo" sort="Matsumoto, Mineo" uniqKey="Matsumoto M" first="Mineo" last="Matsumoto">Mineo Matsumoto</name>
<affiliation wicri:level="3"><nlm:affiliation>Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Pharmaceuticals and Medical Devices Agency, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
<region type="région">Région de Kantō</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hester, Susan" sort="Hester, Susan" uniqKey="Hester S" first="Susan" last="Hester">Susan Hester</name>
<affiliation wicri:level="2"><nlm:affiliation>Office of Research and Development, Environmental Protection Agency, Research Triangle Park, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Office of Research and Development, Environmental Protection Agency, Research Triangle Park, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wehmas, Leah" sort="Wehmas, Leah" uniqKey="Wehmas L" first="Leah" last="Wehmas">Leah Wehmas</name>
<affiliation wicri:level="2"><nlm:affiliation>Office of Research and Development, Environmental Protection Agency, Research Triangle Park, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Office of Research and Development, Environmental Protection Agency, Research Triangle Park, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Botten, Jason W" sort="Botten, Jason W" uniqKey="Botten J" first="Jason W" last="Botten">Jason W. Botten</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT</wicri:regionArea>
<placeName><region type="state">Vermont</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bruce, Emily A" sort="Bruce, Emily A" uniqKey="Bruce E" first="Emily A" last="Bruce">Emily A. Bruce</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT</wicri:regionArea>
<placeName><region type="state">Vermont</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">EMBO molecular medicine</title>
<idno type="eISSN">1757-4684</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (genetics)</term>
<term>Betacoronavirus (isolation & purification)</term>
<term>Clinical Laboratory Techniques (MeSH)</term>
<term>Coronavirus Infections (diagnosis)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (virology)</term>
<term>Global Health (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (diagnosis)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (virology)</term>
<term>RNA, Viral (analysis)</term>
<term>Reverse Transcriptase Polymerase Chain Reaction (MeSH)</term>
<term>Strategic Planning (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ARN viral (analyse)</term>
<term>Betacoronavirus (génétique)</term>
<term>Betacoronavirus (isolement et purification)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (diagnostic)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Pandémies (MeSH)</term>
<term>Planification stratégique (MeSH)</term>
<term>Pneumopathie virale (diagnostic)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>RT-PCR (MeSH)</term>
<term>Santé mondiale (MeSH)</term>
<term>Techniques de laboratoire clinique (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>RNA, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>ARN viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Laboratory Techniques</term>
<term>Global Health</term>
<term>Humans</term>
<term>Pandemics</term>
<term>Reverse Transcriptase Polymerase Chain Reaction</term>
<term>Strategic Planning</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Pandémies</term>
<term>Planification stratégique</term>
<term>RT-PCR</term>
<term>Santé mondiale</term>
<term>Techniques de laboratoire clinique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Current demand for SARS-CoV-2 testing is straining material resource and labor capacity around the globe. As a result, the public health and clinical community are hindered in their ability to monitor and contain the spread of COVID-19. Despite broad consensus that more testing is needed, pragmatic guidance toward realizing this objective has been limited. This paper addresses this limitation by proposing a novel and geographically agnostic framework (the 4Ps framework) to guide multidisciplinary, scalable, resource-efficient, and achievable efforts toward enhanced testing capacity. The 4Ps (Prioritize, Propagate, Partition, and Provide) are described in terms of specific opportunities to enhance the volume, diversity, characterization, and implementation of SARS-CoV-2 testing to benefit public health. Coordinated deployment of the strategic and tactical recommendations described in this framework has the potential to rapidly expand available testing capacity, improve public health decision-making in response to the COVID-19 pandemic, and/or to be applied in future emergent disease outbreaks.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32375201</PMID>
<DateCompleted><Year>2020</Year>
<Month>06</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>09</Month>
<Day>09</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>12</Volume>
<Issue>6</Issue>
<PubDate><Year>2020</Year>
<Month>06</Month>
<Day>08</Day>
</PubDate>
</JournalIssue>
<Title>EMBO molecular medicine</Title>
<ISOAbbreviation>EMBO Mol Med</ISOAbbreviation>
</Journal>
<ArticleTitle>'All In': a pragmatic framework for COVID-19 testing and action on a global scale.</ArticleTitle>
<Pagination><MedlinePgn>e12634</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.15252/emmm.202012634</ELocationID>
<Abstract><AbstractText>Current demand for SARS-CoV-2 testing is straining material resource and labor capacity around the globe. As a result, the public health and clinical community are hindered in their ability to monitor and contain the spread of COVID-19. Despite broad consensus that more testing is needed, pragmatic guidance toward realizing this objective has been limited. This paper addresses this limitation by proposing a novel and geographically agnostic framework (the 4Ps framework) to guide multidisciplinary, scalable, resource-efficient, and achievable efforts toward enhanced testing capacity. The 4Ps (Prioritize, Propagate, Partition, and Provide) are described in terms of specific opportunities to enhance the volume, diversity, characterization, and implementation of SARS-CoV-2 testing to benefit public health. Coordinated deployment of the strategic and tactical recommendations described in this framework has the potential to rapidly expand available testing capacity, improve public health decision-making in response to the COVID-19 pandemic, and/or to be applied in future emergent disease outbreaks.</AbstractText>
<CopyrightInformation>© 2020 The Authors. Published under the terms of the CC BY 4.0 license.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pettit</LastName>
<ForeName>Syril D</ForeName>
<Initials>SD</Initials>
<Identifier Source="ORCID">0000-0002-4320-5343</Identifier>
<AffiliationInfo><Affiliation>Health and Environmental Sciences Institute, Washington, DC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jerome</LastName>
<ForeName>Keith R</ForeName>
<Initials>KR</Initials>
<AffiliationInfo><Affiliation>Virology Division, Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rouquié</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>SAS Bayer Crop Science, Sophia Antipolis, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mari</LastName>
<ForeName>Bernard</ForeName>
<Initials>B</Initials>
<Identifier Source="ORCID">0000-0002-0422-9182</Identifier>
<AffiliationInfo><Affiliation>Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), CNRS, Université Côte d'Azur, Valbonne, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Barbry</LastName>
<ForeName>Pascal</ForeName>
<Initials>P</Initials>
<Identifier Source="ORCID">0000-0001-9632-6483</Identifier>
<AffiliationInfo><Affiliation>Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), CNRS, Université Côte d'Azur, Valbonne, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kanda</LastName>
<ForeName>Yasunari</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>National Institute of Health Sciences, Kanagawa, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Matsumoto</LastName>
<ForeName>Mineo</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hester</LastName>
<ForeName>Susan</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Office of Research and Development, Environmental Protection Agency, Research Triangle Park, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wehmas</LastName>
<ForeName>Leah</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Office of Research and Development, Environmental Protection Agency, Research Triangle Park, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Botten</LastName>
<ForeName>Jason W</ForeName>
<Initials>JW</Initials>
<Identifier Source="ORCID">0000-0001-6839-0306</Identifier>
<AffiliationInfo><Affiliation>Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bruce</LastName>
<ForeName>Emily A</ForeName>
<Initials>EA</Initials>
<Identifier Source="ORCID">0000-0001-8391-370X</Identifier>
<AffiliationInfo><Affiliation>Division of Immunobiology, Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P30 GM118228</GrantID>
<Acronym>GM</Acronym>
<Agency>NIGMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>05</Month>
<Day>27</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>EMBO Mol Med</MedlineTA>
<NlmUniqueID>101487380</NlmUniqueID>
<ISSNLinking>1757-4676</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Protocol" UI="C000657964">COVID-19 diagnostic testing</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019411" MajorTopicYN="N">Clinical Laboratory Techniques</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014943" MajorTopicYN="Y">Global Health</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020133" MajorTopicYN="N">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000070318" MajorTopicYN="N">Strategic Planning</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>6</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32375201</ArticleId>
<ArticleId IdType="doi">10.15252/emmm.202012634</ArticleId>
<ArticleId IdType="pmc">PMC7267598</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Bull World Health Organ. 2017 Sep 1;95(9):639-645</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28867844</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunotoxicol. 2020 Dec;17(1):51-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32124652</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2020 Jul 23;58(8):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32317257</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO Mol Med. 2020 Jun 8;12(6):e12634</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32375201</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
<li>Japon</li>
<li>États-Unis</li>
</country>
<region><li>Caroline du Nord</li>
<li>District de Columbia</li>
<li>Région de Kantō</li>
<li>Vermont</li>
<li>Washington (État)</li>
</region>
<settlement><li>Seattle</li>
<li>Tokyo</li>
</settlement>
<orgName><li>Université de Washington</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="District de Columbia"><name sortKey="Pettit, Syril D" sort="Pettit, Syril D" uniqKey="Pettit S" first="Syril D" last="Pettit">Syril D. Pettit</name>
</region>
<name sortKey="Botten, Jason W" sort="Botten, Jason W" uniqKey="Botten J" first="Jason W" last="Botten">Jason W. Botten</name>
<name sortKey="Bruce, Emily A" sort="Bruce, Emily A" uniqKey="Bruce E" first="Emily A" last="Bruce">Emily A. Bruce</name>
<name sortKey="Hester, Susan" sort="Hester, Susan" uniqKey="Hester S" first="Susan" last="Hester">Susan Hester</name>
<name sortKey="Jerome, Keith R" sort="Jerome, Keith R" uniqKey="Jerome K" first="Keith R" last="Jerome">Keith R. Jerome</name>
<name sortKey="Wehmas, Leah" sort="Wehmas, Leah" uniqKey="Wehmas L" first="Leah" last="Wehmas">Leah Wehmas</name>
</country>
<country name="France"><noRegion><name sortKey="Rouquie, David" sort="Rouquie, David" uniqKey="Rouquie D" first="David" last="Rouquié">David Rouquié</name>
</noRegion>
<name sortKey="Barbry, Pascal" sort="Barbry, Pascal" uniqKey="Barbry P" first="Pascal" last="Barbry">Pascal Barbry</name>
<name sortKey="Mari, Bernard" sort="Mari, Bernard" uniqKey="Mari B" first="Bernard" last="Mari">Bernard Mari</name>
</country>
<country name="Japon"><noRegion><name sortKey="Kanda, Yasunari" sort="Kanda, Yasunari" uniqKey="Kanda Y" first="Yasunari" last="Kanda">Yasunari Kanda</name>
</noRegion>
<name sortKey="Matsumoto, Mineo" sort="Matsumoto, Mineo" uniqKey="Matsumoto M" first="Mineo" last="Matsumoto">Mineo Matsumoto</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001881 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001881 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32375201
   |texte=   'All In': a pragmatic framework for COVID-19 testing and action on a global scale.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32375201" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidFranceV1

This area was generated with Dilib version V0.6.37.
Data generation: Tue Oct 6 23:31:36 2020. Site generation: Fri Feb 12 22:48:37 2021

	Serveur d'exploration sur la COVID en France
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la COVID en France

'All In': a pragmatic framework for COVID-19 testing and action on a global scale.

'All In': a pragmatic framework for COVID-19 testing and action on a global scale.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki